Overall rank by patents
#42,617
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Race Oncology Ltd.
USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, active 2018–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
2
CPC technology areas
12.3
Avg claims per patent
+0%
5-year filing velocity
The verdict
Race holds 6 US patents across 2 technology areas, rank #42,617 of 50,000 tracked assignees.
- #42,617
- of 50,000 US assignees by volume
- Top 94%
- by Innovation Score (19.1/100)
- 12.3
- avg claims per patent
- +0%
- filing velocity, last 5 yrs
Portfolio overview
Race Oncology Ltd. has been granted 6 US utility patents between 2018 and 2021, placing Race Oncology Ltd. at rank #42,617 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Race Oncology Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Race sits between RTR Technologies, Inc. (6 patents, rank #42,613) and Radical Plastics, Inc. (6 patents, rank #42,621) - the closest US assignees by grant volume. The composite Innovation Score of 19.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 3 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Race Oncology Ltd.'s 12.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Race Oncology Ltd. against peers pursuing similar technology classes.
Who files at Race's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- RTR
RTR Technologies, Inc.
6 patents
- Runtech Systems OY
RUNTECH SYSTEMS OY
6 patents
- RV Lizenz
RV Lizenz AG
6 patents
- RVT Group
RVT GROUP LIMITED
6 patents
- Rad Technology Me…
Rad Technology Medical Systems LLC
6 patents
- Radiadyne
RadiaDyne LLC
6 patents
- Radiance Therapeu…
Radiance Therapeutics, Inc.
6 patents
- Radical Plastics
Radical Plastics, Inc.
6 patents
- Race Oncology ◀
Race Oncology Ltd.
6 patents
What this shows Race holds 6 patents at rank #42,617, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Race
By rank, the assignees closest to #42,617 in granted patent volume.
- RTR Technologies, Inc. #42,613 · 6 patents
- Runtech Systems OY #42,614 · 6 patents
- RV Lizenz Ag #42,615 · 6 patents
- RVT Group Limited #42,616 · 6 patents
- Rad Technology Medical Systems Llc #42,618 · 6 patents
- Radiadyne Llc #42,619 · 6 patents
- Radiance Therapeutics, Inc. #42,620 · 6 patents
- Radical Plastics, Inc. #42,621 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Race's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Race's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
19 Top 94% higher than 6% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 33.3% |
| 2019 | 1 | 16.7% |
| 2020 | 1 | 16.7% |
| 2021 | 2 | 33.3% |
Which technologies does Race Oncology Ltd. patent most?
Top 2 of 2 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Growing
Frequently Asked Questions
How many patents does Race Oncology Ltd. hold?
Race Oncology Ltd. holds 6 US granted patents filed between 2018 and 2021, spanning 2 technology areas.
What is Race Oncology Ltd.'s Innovation Score?
Race Oncology Ltd. has an Innovation Score of 19.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Race Oncology Ltd. focus on?
Race Oncology Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 2 CPC subclasses total.
Is Race Oncology Ltd.'s patent filing rate increasing or decreasing?
Race Oncology Ltd.'s recent filing velocity is +0% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Race Oncology Ltd.'s patents?
Race Oncology Ltd.'s patents average 12.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Race Oncology Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Race's 6 grants land it in the top 94% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Race ranks #42,617 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.